Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo
With
Plexxikon
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 and older
Solid tumors refractory to standard therapy
For the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:
* For advanced or recurrent mucoepidermal carcinoma (MEC) of the salivary gland, patients must not be candidates for curative surgery or radiotherapy.
* For pigmented villo-nodular synovitis (PVNS), patients must have a histologically confirmed diagnosis of inoperable progressive or relapsing PVNS, or resectable tumor requesting mutilating surgery, as well as demonstrated progressive disease in the last 12 months.
* For gastrointestinal stromal tumors (GIST), patients must have failed previous therapy with imatinib and sunitinib. Patients with known PDGFR mutations are excluded, but mutation testing is not required for study entry.
* For anaplastic thyroid cancer (ATC), patients must have histologically or cytologically diagnosed advanced ATC.
* For metastatic solid tumors with documented malignant pleural and/or peritoneal effusions, patients must not be receiving specific therapy for the effusion or have an indwelling drain.
Eastern Cooperative Oncology Group performance status 0 or 1
Life expectancy \>= 3 months
Adequate hepatic, renal, and bone marrow function
You may not be if
Specific anti-cancer therapy within 3 weeks of study start
Uncontrolled intercurrent illness
Refractory nausea or vomiting, or malabsorption
Mean corrected QT interval (QTc) \>= 450 msec (for males) or QTc \>= 470 msec (for females)
Clareo Health | Safety Study of PLX108-01 in Patients With Solid Tumors
